The goal of this observational study is to learn if a strategy can be developed for differentiating autoimmune pancreatitis (AIP) and primary pancreatic lymphoma (PPL) from pancreatic ductal adenocarcinoma (PDAC) in patients presenting with pancreatic masses. The main question it aims to answer is: What features, in the perspectives of clinical manifestation, laboratory tests, and imaging, can differentiate different kinds of pancreatic masses (AIP, PPL and PDAC)? Participants will not be given any interventions since this is a retrospective observational study.
Study Type
OBSERVATIONAL
Enrollment
110
Diagnostic nomogram
Time frame: From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months
serum level of LDH
Time frame: From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months
serum level of IgG4
Time frame: From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months
largest diameter of pancreatic masses
Time frame: From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months
dilation of pancreatic duct
Time frame: From date of admission into the hospital to the establishment of diagnosis, assessed up to 100 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.